56 related articles for article (PubMed ID: 36193009)
1. Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
Smolej L; Vodárek P; Écsiová D; Šimkovič M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201565
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
Fleck C; Karabinos A; Cook A; Moore DC; Jacobs R
Leuk Lymphoma; 2024 Apr; ():1-2. PubMed ID: 38646879
[No Abstract] [Full Text] [Related]
3. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.
Rivano M; Mengato D; Chiumente M; Messori A
Hematol Rep; 2023 Nov; 15(4):670-683. PubMed ID: 38132276
[TBL] [Abstract][Full Text] [Related]
4. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses.
Messori A; Damuzzo V; Rivano M; Cancanelli L; Di Spazio L; Ossato A; Chiumente M; Mengato D
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980518
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
Messori A; Rivano M; Mengato D; Chiumente M
Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
[TBL] [Abstract][Full Text] [Related]
6. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
9. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU; Munir T; Moreno C; Owen C; Follows GA; Benjamini O; Janssens A; Levin MD; Robak T; Simkovic M; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Sinet P; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Kater AP
Lancet Oncol; 2023 Dec; 24(12):1423-1433. PubMed ID: 37944541
[TBL] [Abstract][Full Text] [Related]
10. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
11. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
[TBL] [Abstract][Full Text] [Related]
12. Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.
Messori A
Eur J Haematol; 2023 Jan; 110(1):60-66. PubMed ID: 36193009
[TBL] [Abstract][Full Text] [Related]
13. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
